Summary
Eli Lilly and Company reported robust financial results for the second quarter and first half of 2023, demonstrating significant revenue and net income growth. Total revenue increased by 28% in the second quarter and 7% year-to-date, driven by strong volume increases in key products like Mounjaro, Verzenio, Jardiance, and Taltz, along with a notable contribution from the sale of Baqsimi rights. Net income saw a substantial rise of 85% in the quarter and 9% year-to-date, attributed to higher revenues, reduced acquired in-process R&D charges, and strategic pipeline investments. The company continues to invest heavily in research and development, with expenses increasing by 32% and 28% for the respective periods, reflecting a strong commitment to its late-stage pipeline, including promising treatments for diabetes, obesity, immunology, and neuroscience. Acquisitions, such as the announced deal for DICE Therapeutics, underscore Lilly's strategy to expand its portfolio and therapeutic reach. Despite supply chain challenges for incretin products like Mounjaro and Trulicity, the company is actively expanding manufacturing capacity to meet demand. Looking ahead, Lilly faces potential headwinds from evolving pharmaceutical pricing regulations, including the Inflation Reduction Act, but remains focused on innovation and growth.
Financial Highlights
51 data points| Revenue | $8.31B |
| Cost of Revenue | $1.81B |
| Gross Profit | $6.50B |
| R&D Expenses | $2.36B |
| SG&A Expenses | $1.93B |
| Interest Expense | $120.30M |
| Net Income | $1.76B |
| EPS (Basic) | $1.96 |
| EPS (Diluted) | $1.95 |
| Shares Outstanding (Basic) | 899.70M |
| Shares Outstanding (Diluted) | 902.70M |
Key Highlights
- 1Revenue increased by 28% to $8.31 billion for the three months ended June 30, 2023, and by 7% to $15.27 billion for the six months ended June 30, 2023, driven by strong product sales and strategic divestitures.
- 2Net income significantly grew by 85% to $1.76 billion for the quarter and 9% to $3.11 billion year-to-date, reflecting improved operational efficiency and revenue growth.
- 3Key growth drivers include Mounjaro (obesity/diabetes), Verzenio (oncology), Jardiance (diabetes), and Taltz (immunology), with Mounjaro showing particularly strong performance.
- 4The company is making substantial investments in R&D, with expenses up 32% and 28% for the quarter and year-to-date respectively, indicating a focus on pipeline development.
- 5Eli Lilly announced a definitive agreement to acquire DICE Therapeutics for approximately $2.4 billion, reinforcing its commitment to strategic acquisitions in the biopharmaceutical space.
- 6Despite strong demand, the company is experiencing intermittent supply delays for incretin products like Mounjaro and Trulicity, though it is actively expanding manufacturing capacity.
- 7The sale of rights for Baqsimi contributed $579 million in revenue during the second quarter, significantly boosting top-line results for the period.